SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan. NEW YORK, June ...
SALT LAKE CITY, Oct. 30, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in ...
Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study ...
SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight ® Psychotropic test, ...
Hosted on MSN
GeneSight Testing in 2026 Offers Flexible Ordering, Clear Coverage Rules, and Actionable Reports
In 2026, GeneSight testing allows both clinicians and patients to choose between in-office and at-home DNA collection, with clear insurance coverage criteria and capped self-pay costs. Its color-coded ...
The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
A former pageant winner's crowning achievement has little to do with her pageant titles and everything to do with taking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results